Cut-Price Generics Set To Challenge Boehringer’s Nintedanib In India

Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.

Lungs
India Competition Arrives For Boehringer's Nintedanib • Source: Shutterstock

Front-line Indian firms have thrown down the gauntlet to Boehringer Ingelheim GmbH with the launch on the domestic market of their cut-price versions of nintedanib for idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterized by a decline in lung function.

First off the block appears to have been Sun Pharmaceutical Industries Ltd., the country’s top-ranked drug firm, which signaled...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia